(Reuters) - Noven said it saw an annual sales opportunity from JDS's products, which include drugs for bipolar disorder, depression and panic disorder, in excess of $500 million from 2012, assuming development and regulatory approval on current schedules.
) Keywords: NOVEN JDS
Read more at Reuters.com Mergers News
) Keywords: NOVEN JDS
Read more at Reuters.com Mergers News
No comments:
Post a Comment